128 related articles for article (PubMed ID: 31285125)
1. Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity.
Hai Y; Song P; Wang X; Zhao L; Xie Q; Li J; Li Y; Li H
J Pharmacol Sci; 2019 Jun; 140(2):162-170. PubMed ID: 31285125
[TBL] [Abstract][Full Text] [Related]
2. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
3. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway.
Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY
Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877
[TBL] [Abstract][Full Text] [Related]
4. Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution.
Wang X; Chen B; Zhao L; Zhi D; Hai Y; Song P; Li Y; Xie Q; Inam U; Wu Z; Yu L; Li H
Biomed Pharmacother; 2018 Feb; 98():252-264. PubMed ID: 29272786
[TBL] [Abstract][Full Text] [Related]
5. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
6. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
Liu J; Lu Y; Wu Q; Goyer RA; Waalkes MP
J Pharmacol Exp Ther; 2008 Aug; 326(2):363-8. PubMed ID: 18463319
[TBL] [Abstract][Full Text] [Related]
7. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
[TBL] [Abstract][Full Text] [Related]
8. Studies on curative efficacy of monoterpene eugenol on anti- leukemic drug arsenic trioxide induced cardiotoxicity.
Binu P; Priya N; Abhilash S; Vineetha RC; Nair RH
Biomed Pharmacother; 2017 Jul; 91():559-566. PubMed ID: 28494415
[TBL] [Abstract][Full Text] [Related]
9. The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
Wu J; Shao Y; Liu J; Chen G; Ho PC
J Ethnopharmacol; 2011 Jun; 135(3):595-602. PubMed ID: 21497649
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].
Sun YT; Xu HH; Nie Y; Wang YG; Ma ZC; Zhou W; Tan HL; Gao Y
Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):142-148. PubMed ID: 32237423
[TBL] [Abstract][Full Text] [Related]
11. [Safety evaluation of niuhuang jiedu tablet].
Feng YL; Miao JW; Li J; Sung AS; Liu J
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3221-5. PubMed ID: 25522601
[TBL] [Abstract][Full Text] [Related]
12. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
Pastorek M; Gronesova P; Cholujova D; Hunakova L; Bujnakova Z; Balaz P; Duraj J; Lee TC; Sedlak J
Neoplasma; 2014; 61(6):700-9. PubMed ID: 25150315
[TBL] [Abstract][Full Text] [Related]
13. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
14. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells.
Wang L; Liu S; Gao C; Chen H; Li J; Lu J; Yuan Y; Zheng X; He H; Zhang X; Zhang R; Zhang Y; Wu Y; Lin W; Zheng H
Hum Exp Toxicol; 2022; 41():9603271211064537. PubMed ID: 35195477
[TBL] [Abstract][Full Text] [Related]
16. α-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs.
Kumazaki M; Ando H; Kakei M; Ushijima K; Taniguchi Y; Yoshida M; Yamato S; Washino S; Koshimizu TA; Fujimura A
Eur J Pharmacol; 2013 Apr; 705(1-3):1-10. PubMed ID: 23474023
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Long Non-Coding RNA Kcnq1ot1: An Important Mechanism of Arsenic Trioxide-Induced Long QT Syndrome.
Jiang Y; Du W; Chu Q; Qin Y; Tuguzbaeva G; Wang H; Li A; Li G; Li Y; Chai L; Yue E; Sun X; Wang Z; Pavlov V; Yang B; Bai Y
Cell Physiol Biochem; 2018; 45(1):192-202. PubMed ID: 29339628
[TBL] [Abstract][Full Text] [Related]
18. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
19. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
[TBL] [Abstract][Full Text] [Related]
20. [Asenic accumulation following realgar administration in rats].
Li C; Liang A; Wang J; Xue B; Li H; Yang B; Wang J; Xie Q; Nilsen OG; Zhang B
Zhongguo Zhong Yao Za Zhi; 2011 Jul; 36(14):1895-900. PubMed ID: 22016955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
